BRPI0809509A2 - Composto, composição farmacêutica, métodos para inibir a adesão intracelular mediada pela selectina, e para tratar ou prevenir uma doença ou distúrbio em um mamífero, e, uso de um composto. - Google Patents

Composto, composição farmacêutica, métodos para inibir a adesão intracelular mediada pela selectina, e para tratar ou prevenir uma doença ou distúrbio em um mamífero, e, uso de um composto. Download PDF

Info

Publication number
BRPI0809509A2
BRPI0809509A2 BRPI0809509-4A BRPI0809509A BRPI0809509A2 BR PI0809509 A2 BRPI0809509 A2 BR PI0809509A2 BR PI0809509 A BRPI0809509 A BR PI0809509A BR PI0809509 A2 BRPI0809509 A2 BR PI0809509A2
Authority
BR
Brazil
Prior art keywords
carboxylic acid
group
hydroxy
compound
quinoline
Prior art date
Application number
BRPI0809509-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Kristin Marie Janz
Adrian Huang
Alessandro Fabio Moretto
Patricia Ward Bedard
Neelu Kaila
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0809509A2 publication Critical patent/BRPI0809509A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • C07D221/12Phenanthridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0809509-4A 2007-03-30 2008-03-28 Composto, composição farmacêutica, métodos para inibir a adesão intracelular mediada pela selectina, e para tratar ou prevenir uma doença ou distúrbio em um mamífero, e, uso de um composto. BRPI0809509A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92120307P 2007-03-30 2007-03-30
US60/921203 2007-03-30
PCT/US2008/058654 WO2008121817A2 (en) 2007-03-30 2008-03-28 Quinoline derivatives and pharmaceutical compositions comprising them for selectin inhibition

Publications (1)

Publication Number Publication Date
BRPI0809509A2 true BRPI0809509A2 (pt) 2014-09-16

Family

ID=39730664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809509-4A BRPI0809509A2 (pt) 2007-03-30 2008-03-28 Composto, composição farmacêutica, métodos para inibir a adesão intracelular mediada pela selectina, e para tratar ou prevenir uma doença ou distúrbio em um mamífero, e, uso de um composto.

Country Status (10)

Country Link
US (1) US20080255192A1 (enExample)
EP (1) EP2134692A2 (enExample)
JP (1) JP2010523499A (enExample)
KR (1) KR20090127183A (enExample)
CN (1) CN101646652A (enExample)
AU (1) AU2008232683A1 (enExample)
BR (1) BRPI0809509A2 (enExample)
CA (1) CA2681757A1 (enExample)
MX (1) MX2009010384A (enExample)
WO (1) WO2008121817A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516237A (ja) * 2003-11-10 2007-06-21 ワイス セレクチン阻害のための方法および組成物
US11021427B2 (en) 2018-04-19 2021-06-01 The Scripps Research Institute Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids
JP7129394B2 (ja) * 2019-10-16 2022-09-01 信越化学工業株式会社 2-(1,2,2-トリメチル-3-シクロペンテニル)-2-オキソエチル=カルボキシレート化合物及びヒドロキシメチル=1,2,2-トリメチル-3-シクロペンテニル=ケトンの製造方法、並びにハロメチル=(1,2,2-トリメチル-3-シクロペンテニル)=ケトン化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
JP2007516237A (ja) * 2003-11-10 2007-06-21 ワイス セレクチン阻害のための方法および組成物
EP1682511A2 (en) * 2003-11-10 2006-07-26 Wyeth Methods and compositions for selectin inhibition
TW200738639A (en) * 2005-10-05 2007-10-16 Wyeth Corp Process for the synthesis of compounds for selectin inhibition

Also Published As

Publication number Publication date
AU2008232683A1 (en) 2008-10-09
KR20090127183A (ko) 2009-12-09
WO2008121817A3 (en) 2009-02-12
MX2009010384A (es) 2009-10-16
US20080255192A1 (en) 2008-10-16
CN101646652A (zh) 2010-02-10
JP2010523499A (ja) 2010-07-15
WO2008121817A2 (en) 2008-10-09
EP2134692A2 (en) 2009-12-23
CA2681757A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
JP6856543B2 (ja) ブロモドメイン阻害剤
JP5169821B2 (ja) キノロン誘導体又はその製薬学的に許容される塩
US5478938A (en) Nitrogenous bicyclic derivatives substituted with benzyl
CN104364237B (zh) 组蛋白去乙酰化酶(hdacs)抑制剂
JP2005521698A (ja) 新規な三環式化合物
AU2009262150A1 (en) Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
PT2624695E (pt) Novos compostos de quinolina substituídos como inibidores de s-nitrosoglutationa redutase
CN102124011A (zh) 人类免疫缺陷病毒复制的抑制剂
EP1278734A2 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
WO2006046552A1 (ja) 新規な含窒素複素環化合物およびその塩
JPS582935B2 (ja) 5↓−アロイルピロ−ル誘導体の製造法
RS58786B1 (sr) Novi aminski derivati ili njihove soli kao inhibitori tnf alfa
AU2015346223A1 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
CN106535901A (zh) 新型μ‑阿片受体激动剂
CZ235192A3 (en) Heteroaryl-substituted hydroxylamino derivatives
CA2517446A1 (en) 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists
BRPI0809509A2 (pt) Composto, composição farmacêutica, métodos para inibir a adesão intracelular mediada pela selectina, e para tratar ou prevenir uma doença ou distúrbio em um mamífero, e, uso de um composto.
JPWO2004009556A1 (ja) 4−置換アリール−5−ヒドロキシイソキノリノン誘導体
JPH03181465A (ja) キノリン誘導体
CN104098558A (zh) 酰胺类化合物及其制备方法
JP2010523499A5 (enExample)
US20080125454A1 (en) Methods and Compositions for Treatment of Scleritis and Related Disorders
JPS604816B2 (ja) 2‐(2‐アミノベンゾイル)ピリジンの製造法
EA049518B1 (ru) Трициклический конденсированный гетероциклический двойной ингибитор pde3/4 и его применение
CA2682183A1 (en) Methods and compositions for selectin inhibition

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired